DOPAMINE D3 RECEPTOR OCCUPANCY AND D3 RECEPTOR-MEDIATED ACTIONS OF CARIPRAZINE, A DOPAMINE D3/D2 RECEPTOR PARTIAL AGONIST ANTIPSYCHOTIC CANDIDATE

2014 ◽  
Vol 153 ◽  
pp. S23
Author(s):  
Ashok Rakhit ◽  
Suresh Durgam ◽  
Nika Adham ◽  
István Gyertyán ◽  
Béla Kiss ◽  
...  
Keyword(s):  
Partial Agonist ◽  
D2 Receptor ◽  
Receptor Occupancy ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Dopamine D3

Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor

1992 ◽  
Vol 225 (4) ◽  
pp. 331-337 ◽  
Author(s):  
Pierre Sokoloff ◽  
Marc Andrieux ◽  
Roger Besançon ◽  
Catherine Pilon ◽  
Marie-Pascale Martres ◽  
...  
Keyword(s):  
Cell Line ◽  
Mammalian Cell ◽  
D2 Receptor ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Mammalian Cell Line ◽  
Dopamine D3

RETRACTED: Dopamine D3 receptor partial agonist LS-3-134 attenuates cocaine-motivated behaviors

2018 ◽  
Vol 171 ◽  
pp. 46-53 ◽  
Author(s):  
Gregory L. Powell ◽  
John Paul Bonadonna ◽  
Annika Vannan ◽  
Kuiying Xu ◽  
Robert H. Mach ◽  
...  
Keyword(s):  
Partial Agonist ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Dopamine D3 ◽  
Motivated Behaviors

The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonist

1995 ◽  
Vol 282 (1-3) ◽  
pp. R3-R4 ◽  
Author(s):  
Nathalie Griffon ◽  
Catherine Pilon ◽  
Jean-Charles Schwartz ◽  
Pierre Sokoloff
Keyword(s):  
Partial Agonist ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Receptor Ligand ◽  
Dopamine D3

scholarly journals Dopamine D3 Receptor Ligand Suppresses the Expression of Levodopa-Induced Dyskinesia in Nonhuman Primate Model of Parkinson's Disease

2021 ◽  
Author(s):  
Thomas Oh ◽  
Elyas Daadi ◽  
Jeffrey Kim ◽  
Etienne Daadi ◽  
Peng-Jen Chen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Partial Agonist ◽  
Nigrostriatal System ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Lead Compound ◽  
Primate Model ◽  
Medical Needs ◽  
Dopamine D3

Abstract Parkinson’s disease (PD) is a complex multisystem, chronic and so far incurable disease with significant unmet medical needs. The incidence of PD increases with aging and the expected burden will continue to escalate with our aging population. Since its discovery in the 1961 levodopa remains the gold standard pharmacotherapy for PD. However, the progressive nature of the neurodegenerative process in and beyond the nigrostriatal system causes a multitude of side effects, including levodopa-induced dyskinesia within 5 years of therapy. Attenuating dyskinesia has been a significant challenge in the clinical management of PD. We report on a small molecule that eliminates the expression of levodopa-induced dyskinesia and significantly improves PD-like symptoms. The lead compound PD13R we discovered is a dopamine D3 receptor partial agonist with high affinity and selectivity, orally active and with desirable drug-like properties. Future studies are aimed at developing this lead compound for treating PD patients with dyskinesia.

Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats

2009 ◽  
Vol 616 (1-3) ◽  
pp. 134-140 ◽  
Author(s):  
Megan E. Breuer ◽  
Lucianne Groenink ◽  
Ronald S. Oosting ◽  
Erich Buerger ◽  
Michiel Korte ◽  
...  
Keyword(s):  
Receptor Agonist ◽  
D2 Receptor ◽  
Dopamine D3 Receptor ◽  
D3 Receptor ◽  
Antidepressant Effects ◽  
Dopamine D3 ◽  
D2 Receptor Agonist
Sign in / Sign up

Export Citation Format

Share Document